- Home
- ANIX
as 07-26-2024 4:00pm EST
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 92.5M | IPO Year: | 1987 |
| Target Price: | $7.00 | AVG Volume (30 days): | 151.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.15 - $5.13 | Next Earning Date: | 09-04-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Anixa Biosciences Inc. (ANIX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Titterton Lewis H jr | ANIX | Director | Jun 14 '24 | Buy | $2.68 | 4,000 | $10,720.00 | 860,612 | SEC Form 4 |
| Titterton Lewis H jr | ANIX | Director | Jun 13 '24 | Buy | $2.70 | 405 | $1,093.50 | 856,612 | SEC Form 4 |
| Titterton Lewis H jr | ANIX | Director | Jun 10 '24 | Buy | $2.60 | 330 | $858.00 | 849,105 | SEC Form 4 |
| Titterton Lewis H jr | ANIX | Director | Jun 10 '24 | Buy | $2.66 | 7,102 | $18,891.32 | 856,207 | SEC Form 4 |
| Titterton Lewis H jr | ANIX | Director | Jun 7 '24 | Buy | $2.52 | 10,738 | $27,059.76 | 848,775 | SEC Form 4 |
| KUMAR AMIT | ANIX | Chief Executive Officer | Jun 7 '24 | Buy | $2.41 | 25,000 | $60,250.00 | 516,925 | SEC Form 4 |
| Catelani Michael | ANIX | President, COO, & CFO | Jun 7 '24 | Buy | $2.40 | 6,250 | $15,000.00 | 35,211 | SEC Form 4 |
| Titterton Lewis H jr | ANIX | Director | Apr 9 '24 | Buy | $3.28 | 15,009 | $49,229.52 | 838,037 | SEC Form 4 |
| Baskies Arnold M | ANIX | Director | Mar 15 '24 | Buy | $3.63 | 10,000 | $36,300.00 | 110,000 | SEC Form 4 |
| KUMAR AMIT | ANIX | Chief Executive Officer | Mar 15 '24 | Buy | $3.22 | 30,000 | $96,600.00 | 491,925 | SEC Form 4 |
Latest Anixa Biosciences Inc. News
ANIX Breaking Stock News: Dive into ANIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 hours ago
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely
MT Newswires
3 days ago
Anixa Partner Gets FDA Nod for Second CAR-T Treatment to Ovarian Cancer Patient
PR Newswire
4 days ago
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
Benzinga
4 days ago
EXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T Therapy
MT Newswires
9 days ago
Anixa Biosciences Receives Patent for Breast Cancer Vaccine Technology in Japan
PR Newswire
10 days ago
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
MT Newswires
11 days ago
Anixa Biosciences Launches $5 Million Share Buyback Program; Shares Jump
PR Newswire
12 days ago
Anixa Biosciences Announces $5 Million Share Repurchase Program
Compare ANIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIX Anixa Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.